0451 GMT - The near-term headwinds facing Cochlear are likely to keep overshadowing the hearing-technology maker's longer-term opportunity, UBS analysts warn. They tell clients in a note that the Middle East conflict remains the key swing factor given the risks around order delays and sovereign collections. The analysts say this has already meant that the Australian company's net profit guidance range is wide for how late in the fiscal year it is. They expect management to give a wide guidance range for the next fiscal year, which would allow room at the bottom end for already challenging conditions to worsen. UBS keeps a neutral rating on the stock and cuts its target price 2.8% to 106.00 Australian dollars. Shares are flat at A$103.75. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

June 15, 2026 00:51 ET (04:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.